Live poultry vaccines against highly pathogenic avian influenza viruses

Boravleva, Elizaveta; Gambaryan, A. C.

doi:10.18527/2500-2236-2018-5-1-22-28

Cited by 3 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This underpins our results of no transmission to direct contact chickens. Generally, restoration of pathogenicity of the attenuated vaccine strain back to the pathogenic phenotype is an important distress of MLIV 39 . Shown by the shedding data and confirmed by constantly seronegative direct contact animals, the R65 mono / H17N10 strain could be designated as strongly attenuated in chickens already, making further transmission respective restoration of pathogenicity highly unlikely.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1

et al. 2020

View full text Add to dashboard Cite

Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by establishing human-to-human transmissions. Besides culling measures in infected farms in endemic areas, vaccination is the major tool against HPAIV. However, the mainly used inactivated preparations have several limitations, like application to the individual animal by injection and a reduced efficiency. Here we present a modified live influenza vaccine prototype, which is based on the H17N10 bat influenza virus. The new chimeric vaccine strain R65 mono /H17N10 was able to provide full protection against a lethal challenge infection with HPAIV H5N1 of juvenile and subadult chickens, as well as ferrets after oronasal immunization. In addition, the H5 vaccine prototype cannot reassort with avian influenza viruses and therefore is a promising tool against HPAIV H5 infection, allowing new vaccination strategies for efficient disease control.

show abstract

Section: Discussionmentioning

confidence: 99%

“…None of these approaches has been tested in poultry or ferrets so far. Chickens are used by default for pathogenicity and vaccine efficacy studies for poultry 32 . Ferrets are the mammalian counterpart, used for vaccine safety evaluation 33 .…”

Section: Introductionmentioning

confidence: 99%

A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[13,14]. These discoveries are key for the development of new vaccines and medicines, as they allow for a deeper understanding of the mechanisms of virus adaptation and evolution [15,16,17]. Monitoring the genetic diversity of influenza viruses is important to ensure a rapid response to epizootics, as well as to preserve human health [18].…”

Section: Introductionmentioning

confidence: 99%

The epizootic situation of avian influenza in the Kaluga region

Evstafyev,

Dudin,

Spasskaya

et al. 2024

BIO Web Conf.

View full text Add to dashboard Cite

The article discusses the problems associated with increased virulence of strains due to the high representativeness of the sample of susceptible organisms, the spread of avian influenza and its natural reservoirs. Currently, avian influenza virus strains are divided into HPAI (highly pathogenic) and LPAI (low pathogenic). Registered outbreaks among wild and domestic birds and cases of human infection with influenza viruses of subtypes H5N8, H7N9 and H9N2 indicate an active mutation of the virus and the appearance of “aggressive” strains that can infect not only poultry, but also humans. This article analyzes the current epizootic situation of avian influenza in the Kaluga region for 2022-2023.

show abstract

High immune efficacy against different avian influenza H5N1 viruses due to oral administration of a Saccharomyces cerevisiae-based vaccine in chickens

Han

et al. 2021

Sci Rep

View full text Add to dashboard Cite

A safe and effective vaccine is the best way to control large-scale highly pathogenic avian influenza virus (HPAI) A (H5N1) outbreaks. Saccharomyces cerevisiae (S. cerevisiae) is an ideal mucosal delivery vector for vaccine development, and we have previously shown that conventional administration of a S. cerevisiae-based vaccine (EBY100/pYD1-HA) via injection led to protection against the homologous H5N1 virus in a mouse model. Because the diameter of S. cerevisiae is approximately 10 μm, which results in a severe inflammation by injection route, therefore, oral administration is a more suitable approach for EBY100/pYD1-HA conferring protection in poultry. We extended our work by evaluating the immunogenicity and protective efficacy of oral vaccination with EBY100/pYD1-HA in the chicken model. Oral immunization with EBY100/pYD1-HA could induce robust serum IgG, mucosal IgA and cellular immune responses. Importantly, EBY100/pYD1-HA provided protection against challenges with a homologous and a heterologous H5N1 viruses. These findings suggest that EBY100/pYD1-HA, a promising H5N1 oral vaccine candidate, can avoid potential reassortment of other avian influenza viruses in oral administration of live virus vaccines and overcome the limitations of conventional injection routes. Importantly, this platform will be able to provide opportunities for broader applications in poultry during HPAI A (H5N1) outbreaks.

show abstract

Live poultry vaccines against highly pathogenic avian influenza viruses

Cited by 3 publications

References 58 publications

A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1

A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1

The epizootic situation of avian influenza in the Kaluga region

High immune efficacy against different avian influenza H5N1 viruses due to oral administration of a Saccharomyces cerevisiae-based vaccine in chickens

Contact Info

Product

Resources

About